|Benefit-Cost Summary Statistics Per Participant|
|Taxpayers||$264||Benefits minus costs||($23,894)|
|Participants||$550||Benefit to cost ratio||($0.44)|
|Others||$17||Chance the program will produce|
|Indirect||($8,189)||benefits greater than the costs||0 %|
|Net program cost||($16,537)|
|Benefits minus cost||($23,894)|
|Detailed Monetary Benefit Estimates Per Participant|
|Benefits from changes to:1||Benefits to:|
|Labor market earnings associated with alcohol abuse or dependence||$248||$547||$0||$68||$864|
|Health care associated with alcohol abuse or dependence||$16||$3||$15||$8||$42|
|Property loss associated with alcohol abuse or dependence||$0||$1||$2||$0||$2|
|Adjustment for deadweight cost of program||$0||$0||$0||($8,265)||($8,265)|
|Detailed Annual Cost Estimates Per Participant|
|Annual cost||Year dollars||Summary|
|Program costs||$16,356||2015||Present value of net program costs (in 2016 dollars)||($16,537)|
|Comparison costs||$0||2015||Cost range (+ or -)||10 %|
|Estimated Cumulative Net Benefits Over Time (Non-Discounted Dollars)|
|The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in non-discounted dollars to simplify the “break-even” point from a budgeting perspective. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.|
|Meta-Analysis of Program Effects|
|Outcomes measured||No. of effect sizes||Treatment N||Adjusted effect sizes (ES) and standard errors (SE) used in the benefit-cost analysis||Unadjusted effect size (random effects model)|
|First time ES is estimated||Second time ES is estimated|
|Alcohol use disorder||5||627||-0.133||0.044||45||0.000||0.000||46||-0.133||0.003|
Finigan, M.W., Perkins, T., Zold-Kilbourn, P., Parks, J., & Stringer, M. (2011). Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts. Journal of Substance Abuse Treatment, 41(3), 288-293.
Garbutt, J.C., Kranzler, H.R., O'Malley, S.S., Gastfriend, D.R., Pettinati, H.M., Silverman, B.L., . . . Erich, E.W. (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol use disorder: A randomized controlled trial. JAMA, 293(13), 1617-1625.
Kranzler, H.R., Wesson, D.R., & Billot, L. (2004). Naltrexone depot for treatment of alcohol use disorder: A multicenter, randomized, placebo-controlled clinical trial. Alcoholism: Clinical and Experimental Research, 28(7), 1051-1059.
Kranzler, H.R., Modesto-Lowe, V., & Nuwayser, E.S. (1998). Sustained-release naltrexone for alcoholism treatment: A preliminary study. Alcoholism: Clinical and Experimental Research, 22(5), 1074-1079.
Pettinati, H.M., Kampman, K.M., Lynch, K.G., Dundon, W.D., Mahoney, E.M., Wierzbicki, M.R., & O'Brien, C.P. (2014). A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol use disorder. The American Journal on Addictions, 23(6), 591-597.